FLSM
ANTX icon

Frazier Life Sciences Management’s AN2 Therapeutics ANTX Stock Holding History

Frazier Life Sciences Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,088,889
Closed -$4.49M – 54
2024
Q2 		$4.49M Buy
2,088,889
+700,000
+50% +$1.67M 0.21% 44
2024
Q1 		$4.51M Hold
1,388,889
– – 0.19% 46
2023
Q4 		$28.5M Hold
1,388,889
– – 1.52% 18
2023
Q3 		$22.3M Buy
+1,388,889
New +$15.7M 1.48% 19

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.43M AUM 17.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Frazier Life Sciences Management's ANTX Position: Q3 2024 in Review

Frazier Life Sciences Management sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 2,088,889 shares — an estimated $4.49M sold.

Frazier Life Sciences Management first reported a position in ANTX in Q3 2023 and held it in 4 quarters. The position peaked at $28.5M in Q4 2023. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Frazier Life Sciences Management reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 2,088,889 AN2 Therapeutics shares in Q3 2024, an estimated $4.49M.
  • Frazier Life Sciences Management first reported a position in AN2 Therapeutics in Q3 2023 and held it in 4 quarters.
  • Frazier Life Sciences Management's AN2 Therapeutics position peaked at $28.5M in Q4 2023.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Frazier Life Sciences Management's 13F filing for Q3 2024, filed 15 Nov 2024.